Page last updated: 2024-09-19

malonic acid

Description

malonic acid : An alpha,omega-dicarboxylic acid in which the two carboxy groups are separated by a single methylene group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

dicarboxylic acid : Any carboxylic acid containing two carboxy groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID867
CHEMBL ID7942
CHEBI ID30794
SCHEMBL ID1471092
SCHEMBL ID336
MeSH IDM0095922

Synonyms (95)

Synonym
dicarboxymethane
methanedicarboxylic acid
wln: qv1vq
nsc8124 ,
carboxyacetic acid
usaf ek-695
nsc-8124
h2malo
CHEBI:30794 ,
hooc-ch2-cooh
LMFA01170041
MLI ,
propanedioic acid malonic acid
inchi=1/c3h4o4/c4-2(5)1-3(6)7/h1h2,(h,4,5)(h,6,7
malonic acid (8ci)
1,3-propanedioic acid
ai3-15375
propanedioic acid (9ci)
kyselina malonova [czech]
einecs 205-503-0
brn 1751370
nsc 8124
propanedioic acid
141-82-2
C04025
C00383
alpha,omega-dicarboxylic acid
C02028
dicarboxylic acid
MALONATE ,
dicarboxylate ,
malonic acid
propanediolic acid
metahnedicarboxylic acid
malonic acid, reagentplus(r), 99%
1O4M
bdbm14673
2FAH
DB02175
592A9849-68C3-4635-AA3D-CBC44965EA3A
CHEMBL7942
FT-0690260
FT-0693474
M0028
AKOS000119034
NCGC00248681-01
dtxcid401659
tox21_200534
cas-141-82-2
dtxsid7021659 ,
NCGC00258088-01
SCHEMBL1471092
c3h4o4
propane-1,3-dioic acid
kyselina malonova
hsdb 8437
unii-9kx7zmg0mk
9kx7zmg0mk ,
4-02-00-01874 (beilstein handbook reference)
BP-11453
FT-0628128
FT-0628127
malonic acid [mi]
malonic acid [inci]
S3029
SCHEMBL336
F1908-0177
malonicacid
ch2(cooh)2
methanedicarbonic acid
STR00614
mfcd00002707
J-521669
malonic acid, anhydrous, free-flowing, redi-dri(tm), reagentplus(r), 99%
malonic acid, certified reference material, tracecert(r)
malonic acid, sublimed grade, >=99.95% trace metals basis
malonic acid, saj first grade, >=99.0%
malonic acid, analytical standard
AC8295
malonic acid, 99%
malonic acid, vetec(tm) reagent grade, 98%
Z57965450
malonate dicarboxylic acid
propanedioic acid dithallium salt
LML ,
dicarboxylic acid c3; propanediolic acid; methanedicarboxylic acid
CS-W019962
BCP05571
Q421972
1,3-propanoic acid
SY001875
AMY11201
STL194278
malonic acid, 99.5%
EN300-18457

Research Excerpts

Overview

ExcerptReference
"Malonic aciduria is an extremely rare inborn error of metabolism due to malonyl-CoA decarboxylase deficiency. "( Abily-Donval, L; Bekri, S; Goldenberg, A; Marret, S; Salomons, GS; Snanoudj, S; Sudrié-Arnaud, B; Tebani, A; Torre, S, 2021)
"Malonic acid is a reversible inhibitor of mitochondrial enzyme complex-II, induces energy crisis and free radical generation."( Yuan, C; Zhao, Y; Zheng, L, 2022)
"Malonic acid (MA) is a reversible inhibitor of succinate dehydrogenase (SDH) which induces mitochondrial dysfunction followed by secondary excitotoxicity and apoptosis due to generation of reactive oxygen species. "( Kalonia, H; Kumar, A; Mishra, J; Sharma, N, 2013)
"Malonic acidaemia is an inborn error of metabolism that accumulates malonate, a competitive succinate dehydrogenase (SDH; EC 1.3.99.1) inhibitor. "( Fleck, J; Mello, CF; Ribeiro, MC; Rubin, MA; Schneider, CM; Sinhorin, VD, 2004)
"Malonic aciduria is a rare autosomal recessive disorder caused by deficiency of malonyl-CoA decarboxylase, encoded by the MLYCD gene. "( Ciani, F; Donati, MA; Genuardi, M; la Marca, G; Malvagia, S; Morrone, A; Papi, L; Pasquini, E; Scholte, HR; Zammarchi, E, 2007)

Effects

ExcerptReference
"Malonic acid derivatives have been successfully applied in a Ag-catalyzed decarboxylative fluorination reaction, providing an unprecedented route to either gem-difluoroalkanes or α-fluorocarboxylic acids by the judicious selection of base and solvent. "( Chen, JP; Guo, CY; Wang, Z; Yang, C, 2019)
"Malonic acid has been observed in the free troposphere and as a component of tropospheric aerosol, among other dicarboxylic acids. "( Beyer, KD; Reusch, B; Richardson, M, 2011)
"N-Malonic acid conjugates have been previously isolated from peanut either as a natural constituent or after feeding with xenobiotics."( Feser, C; Heller, W; Matern, U, 1984)

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
alpha,omega-dicarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

malonic acid is involved in 3 pathway(s), involving a total of 24 unique proteins and 544 unique compounds

PathwayProteinsCompounds
Leucine, isoleucine and valine metabolism2470
fatty acid u03C9-oxidation08
Biochemical pathways: part I0466

Protein Targets (42)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency54.59350.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency0.21730.000714.592883.7951AID1259369
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency47.87770.001022.650876.6163AID1224838; AID1224839; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency43.75330.000214.376460.0339AID720692
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.09710.001530.607315,848.9004AID1224841
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency9.795219.739145.978464.9432AID1159509
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency19.37050.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Phosphoenolpyruvate carboxykinaseGallus gallus (chicken)Ki50,000.000050,000.000050,000.000050,000.0000AID977610
D-aspartate oxidase Rattus norvegicus (Norway rat)Ki1,562.00005.89005.89005.8900AID1247847
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00000.00020.533510.0000AID1797268; AID224309
D-amino-acid oxidaseHomo sapiens (human)IC50 (µMol)10,000.00000.00401.119910.0000AID1247844; AID726222
D-aspartate oxidaseMus musculus (house mouse)Ki1,220.00008.69008.69008.6900AID1247848
D-aspartate oxidaseHomo sapiens (human)IC50 (µMol)1,117.00000.00400.39370.8550AID1247843; AID726223
D-aspartate oxidaseHomo sapiens (human)Ki153.00003.80003.80003.8000AID1247846
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (140)

Processvia Protein(s)Taxonomy
lactate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
pyruvate metabolic processL-lactate dehydrogenase A chainHomo sapiens (human)
glycolytic processL-lactate dehydrogenase A chainHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
primary ovarian follicle growthProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of cytokine productionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
learning or memoryProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mechanical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to acidic pHProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of gene expressionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of glucose metabolic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein processingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of smooth muscle cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
macroautophagyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
forebrain developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
T cell costimulationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of protein-containing complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein destabilizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to nutrient levelsProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to insulin stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of integrin activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of toll-like receptor 3 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
adherens junction organizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
substrate adhesion-dependent cell spreadingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of dephosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of hippo signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intracellular signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
entry of bacterium into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
osteoclast developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ERBB2 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiotensin-activated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
odontogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of vascular permeabilityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stress fiber assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transcytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Notch signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Ras protein signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein autophosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
oogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
leukocyte migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mineralocorticoidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
myoblast proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to electrical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of mitochondrial depolarizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomerase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
uterus developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in mammary gland duct morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell projection assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intestinal epithelial cell developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
interleukin-6-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hydrogen peroxideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to interleukin-1Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to lipopolysaccharideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to peptide hormone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to progesterone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fatty acidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hypoxiaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fluid shear stressProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of podosome assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
DNA biosynthetic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of heart rate by cardiac conductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein localization to nucleusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of TORC1 signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to prolactinProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of male germ cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ovarian follicle developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of lamellipodium morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of early endosome to late endosome transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of anoikisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of caveolin-mediated endocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
innate immune responseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
symbiont entry into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
proline catabolic processD-amino-acid oxidaseHomo sapiens (human)
digestionD-amino-acid oxidaseHomo sapiens (human)
D-amino acid catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine catabolic processD-amino-acid oxidaseHomo sapiens (human)
dopamine biosynthetic processD-amino-acid oxidaseHomo sapiens (human)
D-alanine catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine metabolic processD-amino-acid oxidaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumD-amino-acid oxidaseHomo sapiens (human)
inseminationD-aspartate oxidaseHomo sapiens (human)
grooming behaviorD-aspartate oxidaseHomo sapiens (human)
regulation of cell communicationD-aspartate oxidaseHomo sapiens (human)
D-amino acid catabolic processD-aspartate oxidaseHomo sapiens (human)
hormone metabolic processD-aspartate oxidaseHomo sapiens (human)
nervous system processD-aspartate oxidaseHomo sapiens (human)
aspartate catabolic processD-aspartate oxidaseHomo sapiens (human)
L-serine metabolic processSerine racemaseHomo sapiens (human)
serine family amino acid metabolic processSerine racemaseHomo sapiens (human)
response to xenobiotic stimulusSerine racemaseHomo sapiens (human)
response to organic cyclic compoundSerine racemaseHomo sapiens (human)
response to lipopolysaccharideSerine racemaseHomo sapiens (human)
pyruvate biosynthetic processSerine racemaseHomo sapiens (human)
D-serine metabolic processSerine racemaseHomo sapiens (human)
D-serine biosynthetic processSerine racemaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
L-lactate dehydrogenase activityL-lactate dehydrogenase A chainHomo sapiens (human)
protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
identical protein bindingL-lactate dehydrogenase A chainHomo sapiens (human)
cadherin bindingL-lactate dehydrogenase A chainHomo sapiens (human)
protein kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein kinase C bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
insulin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase activator activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
enzyme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
heme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nuclear estrogen receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
SH2 domain bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane transporter bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cadherin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATPase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phosphoprotein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
BMP receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
connexin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
scaffold protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
D-amino-acid oxidase activityD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-amino-acid oxidaseHomo sapiens (human)
identical protein bindingD-amino-acid oxidaseHomo sapiens (human)
FAD bindingD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-aspartate oxidaseHomo sapiens (human)
D-aspartate oxidase activityD-aspartate oxidaseHomo sapiens (human)
D-glutamate oxidase activityD-aspartate oxidaseHomo sapiens (human)
FAD bindingD-aspartate oxidaseHomo sapiens (human)
magnesium ion bindingSerine racemaseHomo sapiens (human)
L-serine ammonia-lyase activitySerine racemaseHomo sapiens (human)
calcium ion bindingSerine racemaseHomo sapiens (human)
protein bindingSerine racemaseHomo sapiens (human)
ATP bindingSerine racemaseHomo sapiens (human)
D-serine ammonia-lyase activitySerine racemaseHomo sapiens (human)
glycine bindingSerine racemaseHomo sapiens (human)
threonine racemase activitySerine racemaseHomo sapiens (human)
PDZ domain bindingSerine racemaseHomo sapiens (human)
pyridoxal phosphate bindingSerine racemaseHomo sapiens (human)
serine racemase activitySerine racemaseHomo sapiens (human)
identical protein bindingSerine racemaseHomo sapiens (human)
protein homodimerization activitySerine racemaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
nucleusL-lactate dehydrogenase A chainHomo sapiens (human)
cytosolL-lactate dehydrogenase A chainHomo sapiens (human)
membraneL-lactate dehydrogenase A chainHomo sapiens (human)
extracellular exosomeL-lactate dehydrogenase A chainHomo sapiens (human)
oxidoreductase complexL-lactate dehydrogenase A chainHomo sapiens (human)
mitochondrionL-lactate dehydrogenase A chainHomo sapiens (human)
podosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nucleoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
lysosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
late endosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
actin filamentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
caveolaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell junctionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ruffle membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic growth coneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
membrane raftProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular exosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
synaptic membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
glutamatergic synapseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
postsynaptic specialization, intracellular componentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic filopodiumProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial outer membraneD-amino-acid oxidaseHomo sapiens (human)
extracellular regionD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomal matrixD-amino-acid oxidaseHomo sapiens (human)
cytosolD-amino-acid oxidaseHomo sapiens (human)
cell projectionD-amino-acid oxidaseHomo sapiens (human)
presynaptic active zoneD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomeD-aspartate oxidaseHomo sapiens (human)
peroxisomal matrixD-aspartate oxidaseHomo sapiens (human)
cytosolD-aspartate oxidaseHomo sapiens (human)
cytoplasmD-aspartate oxidaseHomo sapiens (human)
cytoplasmSerine racemaseHomo sapiens (human)
cytosolSerine racemaseHomo sapiens (human)
neuronal cell bodySerine racemaseHomo sapiens (human)
apical part of cellSerine racemaseHomo sapiens (human)
cytoplasmSerine racemaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1246864Inhibition of human recombinant serine racemase expressed in Escherichia coli Rosetta 2 (DE3) cells using L-serine as substrate by horseradish peroxidase based couple assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Expanding the chemical space of human serine racemase inhibitors.
AID1247858Inhibition of HA-tagged human DDO expressed in human HeLa cells assessed as increase of L-Asp level at 1000 uM after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1247855Effect on L-Asp level in human HeLa cells at 1000 uM after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1449688Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID429166Inhibition of wild type human recombinant mitochondrial NADP-ME expressed in Escherichia coli BL21 assessed as residual enzyme activity by spectrophotometry in absence of fumarate2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Effects of structural analogues of the substrate and allosteric regulator of the human mitochondrial NAD(P)+-dependent malic enzyme.
AID1247850Effect on D-Asp level in human HeLa cells at 1000 uM after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1246863Inhibition of hexa-His-tagged purified human recombinant serine racemase expressed in Escherichia coli BL21 Codonplus (DE3)-RIL cells assessed as reduction in beta-elimination of L-serine at by spectrophotomtery2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Expanding the chemical space of human serine racemase inhibitors.
AID726220Inhibition of human recombinant N-terminal His-tagged serine racemase expressed in Escherichia coli BL21(DE3) using L-serine as substrate after 10 mins by fluorescence assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Identification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro.
AID1246862Inhibition of hexa-His-tagged purified human recombinant serine racemase expressed in Escherichia coli BL21 Codonplus (DE3)-RIL cells assessed as reduction in beta-elimination of L-serine at 330 uM by spectrophotomtery2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Expanding the chemical space of human serine racemase inhibitors.
AID1174257Inhibition of mouse serine racemase by Lineweaver-Burk plot2015European journal of medicinal chemistry, Jan-07, Volume: 89Malonate-based inhibitors of mammalian serine racemase: kinetic characterization and structure-based computational study.
AID1453915Inhibition of human serine racemase C2D2 mutant assessed as remaining enzyme activity by measuring D-serine production using L-serine as substrate incubated for > 8 hrs2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
A novel serine racemase inhibitor suppresses neuronal over-activation in vivo.
AID233504Ionization constant (pKa2) by treating potentiometric titration data according to the method Noyes1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides.
AID429164Inhibition of human mitochondrial NADP-ME E59L mutant expressed in Escherichia coli XL-1 assessed as residual enzyme activity by spectrophotometry in presence of fumarate2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Effects of structural analogues of the substrate and allosteric regulator of the human mitochondrial NAD(P)+-dependent malic enzyme.
AID1247844Inhibition of human recombinant DAO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1174256Inhibition of mouse serine racemase using L-serine substrate by reversed-phase HPLC analysis2015European journal of medicinal chemistry, Jan-07, Volume: 89Malonate-based inhibitors of mammalian serine racemase: kinetic characterization and structure-based computational study.
AID1247845Competitive inhibition of human recombinant DDO expressed in Escherichia coli BL21(DE3) using D-Asp by Lineweaver-Burk plot analysis2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1449696Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as increase in localization of protein mutant in plasma membrane at 1 to 30 mM after 12 hrs by DAPI staining based immunofluorescence mi2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID1247846Binding affinity to human recombinant DDO2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1185880Binding affinity to serine recemase (unknown origin)2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
In silico and pharmacological screenings identify novel serine racemase inhibitors.
AID726223Inhibition of human recombinant N-terminal His-tagged DDO expressed in Escherichia coli BL21(DE3) using D-aspartate as substrate by colorimetric assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Identification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro.
AID1185878Inhibition of full length human recombinant serine recemase C2DC6D mutant expressed in Escherichia coli BL21 (DE3) assessed as D-serine production after 10 mins by Saccharomyces cerevisiae Dsd1SC based D-serine detection assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
In silico and pharmacological screenings identify novel serine racemase inhibitors.
AID443635Inhibition of mouse recombinant serine racemase transfected in bacterial expression system2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor.
AID726222Inhibition of human recombinant N-terminal His-tagged DAO expressed in Escherichia coli BL21(DE3) using D-serine as substrate by colorimetric assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Identification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro.
AID726218Binding affinity to human recombinant N-terminal His-tagged DAO expressed in Escherichia coli BL21(DE3) at 40 uM after 2 to 30 mins by absorption spectra analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Identification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro.
AID224309Inhibitory activity against SH2 domain of human p60 c-Src tyrosine kinase using surface plasmon resonance (SPR) assay.2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
AID1247843Inhibition of human recombinant DDO expressed in Escherichia coli BL21(DE3) using D-Asp and D-Ala assessed as 2-oxo acid production after 10 mins by colorimetric assay2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1247848Inhibition of mouse recombinant DDO using D-Asp2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID429165Inhibition of human mitochondrial NADP-ME E59L mutant expressed in Escherichia coli XL-1 assessed as residual enzyme activity by spectrophotometry in absence of fumarate2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Effects of structural analogues of the substrate and allosteric regulator of the human mitochondrial NAD(P)+-dependent malic enzyme.
AID121636In vivo antileukemic activity against P-388 lymphocytic leukemia in BDF1 male mice at 0.6(mg/kg)/day intraperitoneal dose expressed as T/C1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Antitumor agents. 44. Bis(helenalinyl) esters and related derivatives as novel potent antileukemic agents.
AID1247852Inhibition of HA-tagged human DDO expressed in human HeLa cells assessed as increase of D-Asp level at 1000 uM after 24 hrs by HPLC analysis2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID429167Inhibition of wild type human recombinant mitochondrial NADP-ME expressed in Escherichia coli BL21 assessed as residual enzyme activity by spectrophotometry in presence of fumarate2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Effects of structural analogues of the substrate and allosteric regulator of the human mitochondrial NAD(P)+-dependent malic enzyme.
AID110256Antileukemic activity of compound against the P-388 lymphocytic leukemic BDF1 male mice at 0.6(mg/kg)/day, administered intraperitoneally; 11.0/9.66 (Treated/control)1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Antitumor agents. 44. Bis(helenalinyl) esters and related derivatives as novel potent antileukemic agents.
AID671895Binding affinity to 6-His-tagged human LDHA (2 to 322 amino acid residue) expressed in Escherichia coli BL21 (DE3) cells by NMR analysis in presence of NADH2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
AID1453914Inhibition of human serine racemase C2D2 mutant assessed as remaining enzyme activity by measuring D-serine production using L-serine as substrate at 1 mM incubated for > 8 hrs2017Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14
A novel serine racemase inhibitor suppresses neuronal over-activation in vivo.
AID1247847Inhibition of rat recombinant DDO using D-Asp2015Journal of medicinal chemistry, Sep-24, Volume: 58, Issue:18
Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro.
AID1185879Inhibition of full length human recombinant serine recemase C2DC6D mutant expressed in Escherichia coli BL21 (DE3) assessed as D-serine production at 1 mM after 10 mins by Saccharomyces cerevisiae Dsd1SC based D-serine detection assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
In silico and pharmacological screenings identify novel serine racemase inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2006Biochemistry, Jul-11, Volume: 45, Issue:27
Structural insights into the mechanism of PEPCK catalysis.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Biochemistry, Jul-11, Volume: 45, Issue:27
Structural insights into the mechanism of PEPCK catalysis.
AID1797268Scintillation Proximity Assay (SPA) from Article 10.1021/jm020970s: \\Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.\\2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (866)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990208 (24.02)18.7374
1990's138 (15.94)18.2507
2000's265 (30.60)29.6817
2010's211 (24.36)24.3611
2020's44 (5.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.11%)5.53%
Reviews11 (1.22%)6.00%
Case Studies12 (1.33%)4.05%
Observational0 (0.00%)0.25%
Other881 (97.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (32)

ArticleYear
Protective effect of 3-n-butylphthalide against intrastriatal injection of malonic acid-induced neurotoxicity and biochemical alteration in rats.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, Volume: 155
2022
Caffeic acid and caffeine attenuate toxicity associated with malonic or methylmalonic acid exposure in Drosophila melanogaster.
Naunyn-Schmiedeberg's archives of pharmacology, Volume: 394, Issue: 2
2021
Siderophore-mediated iron removal from chrysotile: Implications for asbestos toxicity reduction and bioremediation.
Journal of hazardous materials, Jan-05, Volume: 341
2018
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Neurobiology of aging, Volume: 32, Issue: 12
2011
Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats.
Neuroscience, Nov-24, Volume: 171, Issue: 1
2010
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.
Glia, Aug-15, Volume: 57, Issue: 11
2009
Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro.
Journal of psychopharmacology (Oxford, England), Volume: 20, Issue: 2
2006
Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions.
Journal of psychopharmacology (Oxford, England), Volume: 20, Issue: 2
2006
1,2,3,4-Tetrahydroisoquinoline protects terminals of dopaminergic neurons in the striatum against the malonate-induced neurotoxicity.
Brain research, Jul-27, Volume: 1051, Issue: 1-2
2005
In vivo studies on the protective role of minocycline against excitotoxicity caused by malonate or N-methyl-d-aspartate.
Experimental neurology, Volume: 191, Issue: 2
2005
Effects of mitochondrial dysfunction on glutamate receptor-mediated neurotoxicity in cultured rat spinal motor neurons.
Brain research, Jul-23, Volume: 1015, Issue: 1-2
2004
Cytotoxicity and photocytotoxicity of a dendritic C(60) mono-adduct and a malonic acid C(60) tris-adduct on Jurkat cells.
Journal of photochemistry and photobiology. B, Biology, Volume: 67, Issue: 3
2002
Neurodegeneration in methylmalonic aciduria involves inhibition of complex II and the tricarboxylic acid cycle, and synergistically acting excitotoxicity.
The Journal of biological chemistry, Apr-26, Volume: 277, Issue: 17
2002
Photo-induced cytotoxicity of malonic acid [C(60)]fullerene derivatives and its mechanism.
Toxicology in vitro : an international journal published in association with BIBRA, Volume: 16, Issue: 1
2002
Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.
Journal of neurochemistry, Volume: 79, Issue: 1
2001
Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.
Journal of neurochemistry, Volume: 77, Issue: 2
2001
Attenuation of malonate toxicity in primary mesencephalic cultures using the GABA transport blocker, NO-711.
Journal of neuroscience research, Apr-01, Volume: 64, Issue: 1
2001
Role of corticostriatal and nigrostriatal inputs in malonate-induced striatal toxicity.
Neuroreport, Jan-22, Volume: 12, Issue: 1
2001
Age-dependence of malonate-induced striatal toxicity.
Experimental brain research, Volume: 134, Issue: 3
2000
Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant.
Journal of neurochemistry, Volume: 75, Issue: 2
2000
Neuroprotective effects of creatine administration against NMDA and malonate toxicity.
Brain research, Mar-31, Volume: 860, Issue: 1-2
2000
Oxidative stress during energy impairment in mesencephalic cultures is not a downstream consequence of a secondary excitotoxicity.
Neuroscience, Volume: 96, Issue: 2
2000
Novel free radical spin traps protect against malonate and MPTP neurotoxicity.
Experimental neurology, Volume: 157, Issue: 1
1999
Excitotoxicity and oxidative stress during inhibition of energy metabolism.
Developmental neuroscience, Volume: 20, Issue: 4-5
1998
Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo.
Journal of neurochemistry, Volume: 66, Issue: 2
1996
Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment.
British journal of cancer, Volume: 68, Issue: 6
1993
Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Volume: 15, Issue: 4
1995
Selective vulnerability of the CA1 region of hippocampus to the indirect excitotoxic effects of malonic acid.
Neuroscience letters, Jun-02, Volume: 192, Issue: 1
1995
Exacerbation of NMDA, AMPA, and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate.
Journal of neurochemistry, Volume: 64, Issue: 5
1995
The mitochondrial inhibitor malonate enhances NMDA toxicity in the neonatal rat striatum.
Brain research. Developmental brain research, Aug-28, Volume: 88, Issue: 1
1995
Comparative effects of several chelating agents on the toxicity, distribution and excretion of aluminium.
Human toxicology, Volume: 7, Issue: 3
1988
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (1)

ArticleYear
Chronic administration of malonic acid produces selective neural degeneration and transient changes in calbindin immunoreactivity in rat striatum.
Experimental neurology, Volume: 134, Issue: 2
1995
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (2)

ArticleYear
Study of naproxen in some aqueous solutions of choline-based deep eutectic solvents: Solubility measurements, volumetric and compressibility properties.
International journal of pharmaceutics, Jun-10, Volume: 564
2019
Solubility, volumetric and compressibility properties of acetaminophen in some aqueous solutions of choline based deep eutectic solvents at T=(288.15 to 318.15) K.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Nov-15, Volume: 109
2017
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (8)

ArticleYear
Determining the solubilities for benzoate, nicotinate, hydrochloride, and malonate salts of bedaquiline.
International journal of pharmaceutics, Nov-05, Volume: 627
2022
Glibenclamide-malonic acid cocrystal with an enhanced solubility and bioavailability.
Drug development and industrial pharmacy, Volume: 48, Issue: 8
2022
Multicomponent solid forms of felodipine: preparation, characterisation, physicochemical and in-vivo studies.
The Journal of pharmacy and pharmacology, Volume: 69, Issue: 3
2017
Organic acids enhance bioavailability of tetracycline in water to Escherichia coli for uptake and expression of antibiotic resistance.
Water research, Nov-15, Volume: 65
2014
87Sr solid-state NMR as a structurally sensitive tool for the investigation of materials: antiosteoporotic pharmaceuticals and bioactive glasses.
Journal of the American Chemical Society, Aug-01, Volume: 134, Issue: 30
2012
Characterization of thermal behavior of deep eutectic solvents and their potential as drug solubilization vehicles.
International journal of pharmaceutics, Aug-13, Volume: 378, Issue: 1-2
2009
Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats.
Neuroscience, Volume: 81, Issue: 1
1997
L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
Journal of medicinal chemistry, Oct-13, Volume: 38, Issue: 21
1995
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (3)

ArticleYear
Ilex paraguariensis Attenuates Changes in Mortality, Behavioral and Biochemical Parameters Associated to Methyl Malonate or Malonate Exposure in Drosophila melanogaster.
Neurochemical research, Volume: 44, Issue: 9
2019
Determination of oxybutynin in pharmaceuticals via reaction with mixed acids anhydrides: application to content uniformity testing.
Journal of fluorescence, Volume: 21, Issue: 2
2011
Further observations of aldosterone response in barnacle muscle fibers.
The American journal of physiology, Volume: 245, Issue: 3
1983
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]